

ROUTINE MONITORING OF DIABETES MELLITUS IN ADULTS AT PRIMARY HEALTH CARE LEVEL, AND SELF-MONITORING OF BLOOD GLUCOSE (SMBG)

TANJA KEMP, MB ChB, MMed (*Int Med*), *Cert Endocrinology & Metabolism (SA) Phys*

Correspondence to: Tanja Kemp (kemp.tanja@gmail.com)

References

1. SEMDSA Guidelines for Diagnosis and Management of Type 2 Diabetes Mellitus for Primary Health Care 2009. JEMDSA 2009;14(1): 55-58.
2. IDF Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005.
3. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care 2010;33(Suppl 1):S11-S61.
4. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
6. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
7. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589.
8. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187-192.
9. Global IDF/ISPAD Guideline for Type 1 Diabetes in Childhood and Adolescence. Brussels: International Diabetes Federation, 2010.
10. IDF Guideline. Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes. Brussels: International Diabetes Federation, 2009.
11. Davis WA, Bruce DG, Davis TM. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006;29:1764-1770.
12. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-1763.
13. O'Kane MJ, Bunting B, Copeland M, Coates VE. Efficacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008;336:1174-1177.
14. IDF Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation, 2007.
15. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464-1476.

HOW TO START AND OPTIMISE INSULIN THERAPY

S MAHARAJ, MB ChB, FCP (SA), Cert Endocrinology

F PIRIE, MB ChB, FCP (SA), MD

I PARUK, MB ChB, FCP (SA), Cert Endocrinology

A MOTALA, MB ChB, MD, FRCP, FCP

Correspondence to: Sureka Maharaj (surekamaharaj@gmail.com)

References

1. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. *Mayo Clin Proc* 2003; 78: 459-467.
2. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes: a progressive disease. *Diabetes* 1995; 44:1249-1258.
3. Holman RR, Paul SJ, Bethel MA *et al*. Ten-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008;359:1577-1589.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 1998;352:837-853.
5. Gæde P, Vedel P, Larsen N *et al*. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. *N Engl J Med* 2003;348:383-393.
6. Dodd AH, Colby AS. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. *Curr Med Res Opin* 2009;25(7):1605-1613.
7. Brown JB, Nichols GA. Glycemic burden of oral agent failure in type 2 diabetes. *Diabetes* 2003; 52(suppl 1):A61-A62.
8. Gerstein HC. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. *Diabet Med* 2006;23(7):736-742.
9. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Scherthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetologia* 2008;51(3):408-416.
10. Raskin P, Braceras R, Schwartz S, Chaykin L, Pei-Ling C, Wynne A. Over 75% of patients with type 2 diabetes reached target A1C by adding biphasic insulin aspart 70/30 to optimised metformin and pioglitazone treatment. *Diabetes* 2006;55:A131.
11. Raskin P, Allen E, Hollander P, *et al*. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care* 2005;28:260-265.
12. Holman RR. Three-year efficacy of complex insulin regimens in type 2 diabetes. *N Engl J Med* 2009;361:1736-1747.
13. Riddle M, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 2003;26:3080-3086.
14. Hermansen K, Davies M, Derezinski T, *et al*. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add on therapy to oral glucose-lowering drugs in insulin naive people with type 2 diabetes. *Diabetes Care* 2006;29:1269-1274.

RENOPROTECTION IN DIABETES MELLITUS

IKECHI G OKPECHI, *MB BS, FWACP, PhD, Cert Nephrol (SA) Phys*

CHARLES R SWANEPOEL, *MB ChB, MRCP (UK), FRCP (Edin)*

Correspondence to: C Swanepoel (Charles.Swanepoel@uct.ac.za)

References

1. Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. *Am J Kidney Dis* 1999;34:795-808.
2. Gnudi L, Viberti G. The link between mechanical stretch and glucose metabolism -- a conceptual advance in understanding diabetic (and non diabetic?) renal disease. *Nephrol Dial Transplant* 2007;22:318-321.
3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ* 1998;317:703-713.
4. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med* 2000;342:145-153.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001;345:851-860.
6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-869.
7. Diabetes Complications and Control Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications of insulin dependent diabetes mellitus. *N Engl J Med* 1993;329: 977-986.
8. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. *Lancet* 1998;352:837-853.
9. Dominguez JH, Tang N, Xu W, et al. Studies of renal injury III: lipid-induced nephropathy in type II diabetes. *Kidney Int* 2000;57:92-104.
10. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. *Kidney Int* 2001;59:260-269.
11. Afshinnia F, Wilt TJ, Duval S, et al. Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. *Nephrol Dial Transplant* 2010;25:1173-1183.
12. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. *N Engl J Med* 2008;358:2433-2446.
13. Heerspink HL, Greene T, Lewis JB, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. *Nephrol Dial Transplant* 2008;23:1946-1954.
14. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. *J Am Soc Nephrol* 2002;13:1615-1625.
15. Lambers HHJ, Fowler MJ, Volgi J, et al. Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. *Diabet Med* 2007;24:1290-1295.
16. Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. *Diabetes Care* 2005;28:2686-2690.
17. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. *Am J Nephrol* 2007;27:605-614.

DIAGNOSIS OF DIABETES IN 2010

JOEL A DAVE, *MB ChB, PhD, FCP (SA), Cert Endocrinology (SA)*

CARSTEN WEINREICH, *MB ChB, FCP (SA)*

Correspondence to: J Dave (joel.dave@uct.ac.za)

References

1. Wild S, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 2004;27(5):1047-1053.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010;33(Suppl 1):S62-S69.
3. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20(7):1183-1197.
4. Genuth S, et al. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003;26(11):3160-3167.
5. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of a WHO/IDF Consultation. 2006. http://www.who.int/diabetes/publications/Definition%20and%20diagnosis%20of%20diabetes_new.pdf (accessed 2 August 2010).
6. Wong TY, et al. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies. *Lancet* 2008;371(9614): 736-743.
7. Balion CM, et al. Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. *Clin Chem Lab Med* 2007;45(9):1180-1185.
8. Diabetes Prevention Programme Research Group. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. *Diabet Med* 2007;24(2):137-144.
9. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care* 2009;32(7):1327-1334.
10. Pani LN, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. *Diabetes Care* 2008;31(10):1991-1996.
11. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. *Diabetes Res Clin Pract* 2010;87(3):415-421.
12. Herman WH, et al. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. *Diabetes Care* 2007; 30(10):2453-2457.

WHAT TYPE OF DIABETES DOES MY PATIENT HAVE AND IS IT RELEVANT?

PETER RAUBENHEIMER, *MB BCh, FCP (SA)*

Correspondence to: Peter Raubenheimer (peter.raubenheimer@uct.ac.za)

References

1. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. *Diabetes* 1979;28:1039-1057.
2. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* 1997;20:1183-1197.
3. Tuomi T, Groop LC, Zimmet PZ, et al. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. *Diabetes* 1993;42(2):359-362.
4. American Diabetes Association. Type 2 diabetes in children and adolescents. *Diabetes Care* 2000;23:381-389.
5. Scott CR, Smith JM, Craddock MM, et al. Characteristics of youth-onset noninsulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. *Pediatrics* 1997;100(1):84-91.
6. Balasubramanyam A, Nalini R, Hampe CS, et al. Syndromes of ketosis-prone diabetes mellitus. *Endocr Rev* 2008;29(3):292-302.
7. Smith RJ, Nathan DM, Arslanian SA, et al. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. *J Clin Endocrinol Metab*. 2010;95(4):1566-1574.
8. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. *N Engl J Med* 2006; 355:467-477.
9. McCarthy MI, Hattersley AT. Learning from molecular genetics: novel insights arising from the definition of genes for monogenic and type 2 diabetes. *Diabetes* 2008;57:2889-2898.
10. Shepherd M, Shields B, Ellard S, et al. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. *Diabet Med* 2009;26:437-441.

MANAGEMENT OF DIABETES IN THE ELDERLY

W F MOLLENTZE, MD, MMed (Int), FCP (SA), FACE, FRCP

Correspondence to: W F Mollentze (mollentzewf@ufs.ac.za)

References

1. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. *J Gerontol A Biol Sci Med Sci* 2009;64A:256-263.
2. Chang AM, Halter JB. Aging and insulin secretion. *Am J Physiol Endocrinol Metab* 2003;284:7-12.
3. Frier BM, Fisher M. Diabetes mellitus. In: Boon NA, Colledge NR, Ralston SR. *Principles and Practice of Medicine*. 21st ed. (International.) Edinburgh: Churchill Livingstone, 803.
4. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. *Gastroenterology* 2008;134(4):981-987.
5. McLarty DG, Kitange HM, Mtinangi BL, et al. Prevalence of diabetes and impaired glucose tolerance in rural Tanzania. *Lancet* 1989;22:871-874.
6. http://www.semdsa.org.za/files/SEMDSA_DM_Guide_2009.pdf (accessed 25 July 2010).
7. European Diabetes Working Party for Older People 2001-2004. Clinical Guidelines for Type 2 Diabetes. <http://www.eugms.org/index.php?pid=30> (accessed 24 July 2010).
8. Lee PG, Cigolli C, Blaum C. The co-occurrence of chronic diseases and geriatric syndromes: The Health and Retirement Study. *J Am Geriatr Soc* 2009;57:511-516.
9. Vischer U-M, Bauduceau B, Bourdel-Marschasson I, et al. A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly. *Diabetes and Metabolism* 2009;35:168-177.
10. Leal J, Gray AM, Clarke PM. Development of life-expectance tables for people with type 2 diabetes. *Eur Heart J* 2009;30:834-839.
11. Colledge NR. Aging and disease. In: Boon NA, Colledge NR, Ralston SR. *Principles and Practice of Medicine*. 21st ed. (International.) Edinburgh: Churchill Livingstone, 166.
12. Whitmar RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycaemic episodes and risk of dementia in older patients with type 2 diabetes. *JAMA* 2009;301:1565-1572.
13. Kramer HJ, Nguyen QD, Curhan D, Hsu C. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes. *JAMA* 2003;289:3273-3277.
14. Rollin P. Palliative care in end-stage renal failure. *Geriatric Medicine* 2009(November):647-650.
15. Knowler WC, Barrett-Connor E, Fowler SE, et al. for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346(6):393-403.
16. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for The STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial. *Lancet* 2002;359:2072-2077.
17. Peterson MJ, Giuliani C, Morey MC, et al. for the Health, Aging and Body Composition Study Research Group. Physical activity as a preventative factor for frailty: The Health, Aging, and Body Composition Study. *J Gerontol A Biol Sci Med Sci* 2009;64A(1):61-68.

DIABETES EDUCATION IN PRIMARY CARE: A PRACTICAL APPROACH USING THE ADDIE MODEL

BOB MASH, MB ChB, DCH (UK), DRCOG (UK), MRCGP (UK), FCFP (SA), PhD

Correspondence to: Bob Mash (rm@sun.ac.za)

References

1. Schwellnus MP, Patel DN, Nossel C, Dreyer M, Whitesman S, Derman EW. Healthy lifestyle interventions in general practice. Part 4: Lifestyle and Diabetes Mellitus. *South African Family Practice* 2009;51(1).
2. Mash B. Motivating behaviour change in the diabetic patient. *CME* 2009;21(10):564-571.
3. Strickland AW. ADDIE. Idaho State University College of Education Science, Math and Technology Education, 2006.
4. Deakin T, McShane CE, Cade JE, Williams RD. Group based training for self-management strategies in people with type 2 diabetes mellitus. *Cochrane Database Syst Rev* 2005;(2):CD003417.
5. International Diabetes Federation. *International Curriculum for Diabetes Education*. Brussels: International Diabetes Federation, 2007.
6. Mash B, Levitt N, Van Vuuren U, Martell R. Improving the diabetic annual review in primary care: An appreciative inquiry in the Cape Town District Health Services. *South African Family Practice* 2008;50(5):50-50d.
7. International Diabetes Federation. *Conversation Map Tools and training now available*, 2009. <http://www.idf.org/conversation-map-tools-and-training-now-available> (accessed 25 July 2010).
8. Love P. Food-based dietary guidelines for the patient with diabetes. *CME* 2009;21(10). Au: Plse check and give page nos
9. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. *Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada*. *Canadian Journal of Diabetes* 2003;27(suppl2):S130.
10. IDF Africa Region Task Group. *Type 2 Diabetes: Clinical Practice Guidelines for sub-Saharan Africa*. Tanzania: International Diabetes Federation, 2006.
11. Rollnick S, Butler CC, Kinnersley P, Gregory J, Mash B. Motivational interviewing. *BMJ* 2010;27:c1900.
12. Godwin M. Conducting a clinical practice audit. Fourteen steps to better patient care. *Canadian Family Physician* 2001;47(11):2331.

MORE ABOUT...DIABETES

DIRK J BLOM, MB ChB, FCP (SA), MMed, PhD

Correspondence to: D Blom (dirk.blom@uct.ac.za)

References

1. Scherthaner G. Diabetes and cardiovascular disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. *Wien Med Wochenschr* 2010;160(1-2):8-19.
2. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008;358(6):580-591.
3. Yudkin JS, Richter B. Intensive glucose control and cardiovascular outcomes. *Lancet* 2009;374(9689):522.
4. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010;362(17):1563-1574.
5. Standards of medical care in diabetes -- 2010. *Diabetes Care* 2010;33(Suppl 1):S11-S61.